{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:19:50Z","timestamp":1782587990441,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":88,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016272","name":"International Atherosclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170793"],"award-info":[{"award-number":["81170793"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370443"],"award-info":[{"award-number":["81370443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006765","name":"Chinese Medical Association","doi-asserted-by":"publisher","award":["14010110548"],"award-info":[{"award-number":["14010110548"]}],"id":[{"id":"10.13039\/501100006765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jacl.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T09:42:01Z","timestamp":1557654121000},"page":"608-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study"],"prefix":"10.1016","volume":"13","author":[{"given":"Claudia","family":"Stefanutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xumin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Morozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2019.05.002_bib1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"39","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.05.002_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (Consensus Statement of the European Atherosclerosis Society)","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.05.002_bib3","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.05.002_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib5","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jacl.2011.04.001","article-title":"Management of familial hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Ito","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2019.05.002_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.atherosclerosissup.2011.06.001","article-title":"Familial hypercholesterolaemia: a model of care for Australasia","volume":"12","author":"Watts","year":"2011","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2019.05.002_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2019.05.002_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2217\/clp.09.7","article-title":"LDL apheresis for familial hypercholesterolemia: value, indications and demand","volume":"4","author":"Watts","year":"2009","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus\u2014Integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacl.2019.01.009","article-title":"Comparative aspects of the care of familial hypercholesterolemia in the \u201cTen Countries Study\u201d","volume":"13","author":"Pang","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.numecd.2010.04.007","article-title":"The 2009 2nd Italian consensus conference on LDL-apheresis","volume":"20","author":"Stefanutti","year":"2010","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2019.05.002_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.5551\/jat.35949","article-title":"Translational research for improving the care of familial hypercholesterolemia: The \u201cTen Countries Study\u201d and Beyond","volume":"23","author":"Watts","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2019.05.002_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.atherosclerosis.2017.01.015","article-title":"Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France","volume":"257","author":"Bruckert","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib15","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jacl.2016.02.009","article-title":"Management of homozygous familial hypercholesterolemia in real-world clinical practice: a report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis","volume":"10","author":"Stefanutti","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/039139889802106s14","article-title":"Comparison of different LDL-apheresis techniques","volume":"21","author":"Stefanutti","year":"1998","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.jacl.2019.05.002_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2019.05.002_bib20","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00029330-200805010-00002","article-title":"Functional analysis of low-density lipoprotein receptor in homozygous familial hypercholesterolemia patients with novel 1439 C--> T mutation of low-density lipoprotein receptor gene","volume":"121","author":"Lin","year":"2008","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jacl.2019.05.002_bib21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jacl.2019.05.002_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1567-5688(09)71805-7","article-title":"LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience","volume":"10","author":"Keller","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2019.05.002_bib24","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.05.002_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-017-0214-7","article-title":"Efficacy and safety of lomitapide in hypercholesterolemia","volume":"17","author":"Liu","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2019.05.002_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2019.05.002_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2019.05.002_bib28","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the PCSK9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.05.002_bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2019.05.002_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1047951115000591","article-title":"Long-term atorvastatin\u2013ezetimibe\u2013probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood","volume":"26","author":"Lin","year":"2016","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jacl.2019.05.002_bib31","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1365-2133.2003.05680.x","article-title":"Homozygous familial hypercholesterolaemia: development of xanthogranuloma in a boy at puberty under long-term low-density lipoprotein apheresis and drug therapy","volume":"149","author":"Saito","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacl.2019.05.002_bib32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1526-0968.2001.00328.x","article-title":"Apheresis technology for prevention and regression of atherosclerosis","volume":"5","author":"Yamamoto","year":"2001","journal-title":"Ther Apher"},{"key":"10.1016\/j.jacl.2019.05.002_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0021-9150(83)90102-8","article-title":"Effects of probucol on homozygous cases of familial hypercholesterolemia","volume":"48","author":"Yamamoto","year":"1983","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib34","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.05.002_bib35","first-page":"740","article-title":"Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia","volume":"84","author":"Ohri","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacl.2019.05.002_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/imj.12444","article-title":"Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies","volume":"44","author":"Page","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jacl.2019.05.002_bib37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MOL.0000000000000402","article-title":"Gene therapy, a promising treatment for familial hypercholesterolaemia","volume":"28","author":"Rotondo","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib38","first-page":"1","article-title":"Low-density lipoprotein apheresis: an evidence-based analysis","volume":"7","year":"2007","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1016\/j.jacl.2019.05.002_bib39","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jacc.2017.06.058","article-title":"Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations","volume":"70","author":"Stein","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2019.05.002_bib40","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.05.002_bib41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosissup.2015.02.002","article-title":"Managing homozygous familial hypercholesterolaemia from cradle to grave","volume":"18","author":"Thompson","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.jacl.2019.05.002_bib42","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00467-018-3906-6","article-title":"Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia\u2014target attainment requires further increase of intensity","volume":"33","author":"Klaus","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jacl.2019.05.002_bib43","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/ATVBAHA.107.160408","article-title":"Vascular calcifications in homozygote familial hypercholesterolemia","volume":"28","author":"Awan","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2019.05.002_bib44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.05.002_bib45","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1161\/01.ATV.0000177811.14176.2b","article-title":"Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation","volume":"25","author":"Civeira","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2019.05.002_bib46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5551\/jat.34405","article-title":"Familial hypercholesterolemia in Asian populations","volume":"23","author":"Zhou","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2019.05.002_bib47","series-title":"Health at a Glance 2017","year":"2017"},{"key":"10.1016\/j.jacl.2019.05.002_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2018.01.034","article-title":"A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)","volume":"270","author":"Kayikcioglu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib49","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/clc.22809","article-title":"Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families","volume":"40","author":"Wu","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2019.05.002_bib50","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2019.05.002_bib51","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/CIRCGENETICS.116.001545","article-title":"Homozygous familial hypercholesterolemia in Spain - Prevalence and phenotype\u2013genotype relationship","volume":"9","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2019.05.002_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jacl.2017.02.010","article-title":"Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia","volume":"11","author":"Sjouke","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2018.08.007","article-title":"Lipoprotein-apheresis in familial hypercholesterolemia: long-term patient compliance in a French cohort","volume":"277","author":"Beliard","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.05.002_bib54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacl.2015.12.009","article-title":"Quality of life in patients treated with lipoprotein apheresis","volume":"10","author":"Rosada","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib55","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacl.2018.05.008","article-title":"Treatment-related and health-related quality of life in lipoprotein apheresis patients","volume":"12","author":"De Gucht","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.05.002_bib56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beem.2013.10.004","article-title":"Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children","volume":"28","author":"Page","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2019.05.002_bib57","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ijcard.2014.04.165","article-title":"Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population","volume":"174","author":"Shi","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2019.05.002_bib58","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype\u2013phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419301771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419301771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:29Z","timestamp":1761831269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287419301771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1933287419301771"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2019.05.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 National Lipid Association.","name":"copyright","label":"Copyright"}]}}